A practical reference on dihexa: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
==== Underage users ==== As with other platforms popular with children, underage users may inadvertently reveal their daily routine and whereabouts, raising concerns of potential misuse by sexual predators. At the time of reporting (2018), TikTok had only two privacy settings, either private or completely public, without any middle ground. Comment sections of "sexy" videos, such as young girls dancing in revealing clothes, were found to contain requests for nude pictures. Despite safety concerns, TikTok began rolling out photo, video, and voice messaging around 2025. As of January 2026, the features are only available in certain regions, including the United States and Canada. In recent years, the US has charged and sentenced sexual predators for illegal activities on TikTok against underage girls. On 22 January 2021, the Italian Data Protection Authority demanded that TikTok temporarily suspend Italian users whose age could not be established. The order came after the death of a 10-year-old Sicilian girl involved in an Internet challenge. TikTok asked its users in Italy to confirm again that they were over 13 years old. By May, over 500,000 accounts had been removed for failing the age check. In July 2021, the Dutch Data Protection Authority fined TikTok €750,000 for offering privacy statements only in English but not in Dutch.
== Table == Below is a table, in pinyin order, of the Chinese names of major organic compounds, radicals, and functional groups. Characters given are in traditional Chinese, followed by simplified Chinese where possible. Since the characters are modern creations, the traditional Chinese characters are analogous (with traditional components in place of simplified components). The Mandarin pronunciation of each character, as said in mainland China, is in pronunciation column. Any Taiwanese pronunciations that differ from the mainland Chinese pronunciations are put in the notes. Other usages of characters are etymologically unrelated to the character's meaning as names for organic compounds, radicals, and functional groups unless otherwise stated. This list is not exhaustive, although many of the other characters used for this purpose can only be found in specialist dictionaries.
Although districts are not formally designated by income, areas closer to the city center, metro stations, or green zones are considered more prestigious. Moscow also contains some government bodies of the Moscow Oblast, although the city is not part of the oblast.
=== Adverse events === Acupuncture is generally safe when administered by an experienced, appropriately trained practitioner using clean-needle technique and sterile single-use needles. When improperly delivered it can cause adverse effects. Accidents and infections are associated with infractions of sterile technique or neglect on the part of the practitioner. To reduce the risk of serious adverse events after acupuncture, acupuncturists should be trained sufficiently. A 2009 overview of Cochrane reviews found acupuncture is not effective for a wide range of conditions. People with serious spinal disease, such as cancer or infection, are not good candidates for acupuncture. Contraindications to acupuncture (conditions that should not be treated with acupuncture) include coagulopathy disorders (e.g. hemophilia and advanced liver disease), warfarin use, severe psychiatric disorders (e.g. psychosis), and skin infections or skin trauma (e.g. burns). Further, electroacupuncture should be avoided at the spot of implanted electrical devices (such as pacemakers). A 2011 systematic review of systematic reviews (internationally and without language restrictions) found that serious complications following acupuncture continue to be reported. Between 2000 and 2009, ninety-five cases of serious adverse events, including five deaths, were reported. Many such events are not inherent to acupuncture but are due to malpractice of acupuncturists. This might be why such complications have not been reported in surveys of adequately trained acupuncturists.
Sources: en.wikipedia.org
=== Use as forage === In former times, Jerusalem artichoke was used as forage for domesticated cattle, horses, and pigs. The plant has valuable nutrient contents and various bioactive compounds, and so is used today as an animal feed source or for the health of several animal species. Pigs, for example, can eat the tuber either dried or directly from the ground or the green plant biomass (stalks and leaves) from the pasture. Washed Jerusalem artichoke tubers can be fed to many animals, and silage produced from the harvested stalks and leaves. The silage has high nutrient values and satisfactory digestion performance for ruminants. Its high inulin content beneficially affects the rumen metabolism and microflora. However, cutting the tops to produce silage greatly reduces the harvest of the tubers. There are also many other Jerusalem artichoke products on the market, such as supplementary feed for horses, dogs, and small animals.
=== Biomedical === Nanoscale particles are used in biomedical applications as drug carriers or imaging contrast agents in microscopy. Anisotropic nanoparticles are a good candidate in biomolecular detection. Moreover, nanoparticles for nucleic acid delivery offer an unprecedented opportunity to overcome some drawbacks related to the delivery, owing to their tunability with diverse physico-chemical properties, they can readily be functionalized with any type of biomolecules/moieties for selective targeting. Using nanoparticles in cancer treatment is being extensively researched. Certain characteristics of the tumor microenvironment, including leaky vasculature and poor lymphatic drainage, lead to the accumulation of NPs in the tumor. This is known as the enhanced permeability and retention (EPR) effect, and is a type of passive targeting. Additionally, ligands that bind to certain expressed or over-expressed receptors in the tumor microenvironment can be conjugated to the surface of nanoparticles to actively target the tumor. The accumulation of nanoparticles in the tumor can reduce adverse side effects, which is a major drawback of chemotherapy. In drug delivery, the acidic pH of the tumor microenvironment is often exploited to increase the release of the drug from pH-sensitive materials. Additionally, some NPs can generate heat under laser irradiation (photothermal therapy) or alternating magnetic field (magnetic hyperthermia), which can both kill cancer cells, and release drugs loaded in the nanoparticle.
In Australian law, most employees have the right to reasonable notice before dismissal, and dismissals must be for a fair reason, however these rights are not universally upheld. At common law, everyone has the right to reasonable notice before either side terminates a contract. The longer that people work for an employer, the more notice becomes reasonable, reflecting the concept of mutual respect. For example, in Quinn v Jack Chia (Australia) Mr Quinn had been initially hired on a contract with a one-month notice, but had worked for years, taking on senior responsibilities, and making personal sacrifices for his employer. The court held he was entitled to 12 months, not one month as the contract had said, given his length of service, seniority and dedication over the years. A longer period of notice could also be expressly or impliedly agreed. For instance, in Walker v Citigroup Global Markets Australia Pty Ltd an investment banker was promised during negotiations that if he took a new position he would get a guarantee bonus after a year's work, and a higher job title, but before the job had begun the employer terminated and argued that Walker was due only one month's notice according to the standard termination clause. The Federal Court held that despite the termination clause, the promise of a bonus indicated the contract was meant to run for at least one year, so Walker was awarded damages for a year, plus damages for loss of opportunity to remain in employment longer.
=== Expression quantitative trait loci (eQTLs) at DBH loci === Genetic variants such as single-nucleotide polymorphisms (SNPs) at DBH loci were found to be associated with DBH activity and are well known expression quantitative trait loci. Allele variants at two regulatory SNPs namely rs1611115 and rs1989787 were shown to affect transcription of this gene. Mutations identified in dopamine β-hydroxylase deficiency and non-synonymous SNPs such as rs6271 in this gene were found to cause defective secretion of the protein from the endoplasmic reticulum.
=== Substrate concentrations === The remaining enzymes of the cycle are controlled by the concentrations of their substrates. Thus, inherited deficiencies in cycle enzymes other than ARG1 do not result in significant decreases in urea production (if any cycle enzyme is entirely missing, death occurs shortly after birth). Rather, the deficient enzyme's substrate builds up, increasing the rate of the deficient reaction to normal. The anomalous substrate buildup is not without cost, however. The substrate concentrations become elevated all the way back up the cycle to NH+4, resulting in hyperammonemia (elevated [NH+4]P). Although the root cause of NH+4 toxicity is not completely understood, a high [NH+4] puts an enormous strain on the NH+4-clearing system, especially in the brain (symptoms of urea cycle enzyme deficiencies include intellectual disability and lethargy). This clearing system involves GLUD1 and GLUL, which decrease the 2-oxoglutarate (2OG) and Glu pools. The brain is most sensitive to the depletion of these pools. Depletion of 2OG decreases the rate of TCAC, whereas Glu is both a neurotransmitter and a precursor to GABA, another neurotransmitter.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.